
    
      This is a roll over study aimed to provide continued access to axitinib (monotherapy or
      combination, according to treatment received in prior axitinib study) to patients who have
      documented stable, or responding disease, or received clinical benefit (as defined by
      protocol) at the time of the prior study closure.
    
  